Leerink Partnrs Has Pessimistic View of Pfizer Q1 Earnings

Pfizer Inc. (NYSE:PFE) – Analysts at Leerink Partnrs decreased their Q1 2025 earnings per share (EPS) estimates for Pfizer in a report issued on Wednesday, February 5th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings of $0.54 per share for the quarter, down from their previous estimate of $0.58. The consensus estimate for Pfizer’s current full-year earnings is $2.96 per share. Leerink Partnrs also issued estimates for Pfizer’s Q4 2025 earnings at $0.80 EPS, FY2025 earnings at $2.99 EPS, FY2027 earnings at $3.01 EPS and FY2028 earnings at $2.63 EPS.

Other equities analysts also recently issued reports about the stock. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Sanford C. Bernstein initiated coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. UBS Group lowered their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Wolfe Research assumed coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. Finally, Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Down 2.3 %

Pfizer stock opened at $25.83 on Thursday. The firm’s 50 day moving average price is $26.29 and its two-hundred day moving average price is $27.78. The firm has a market cap of $146.35 billion, a PE ratio of 34.90, a P/E/G ratio of 0.66 and a beta of 0.64. Pfizer has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS.

Hedge Funds Weigh In On Pfizer

Large investors have recently made changes to their positions in the business. Ethos Financial Group LLC lifted its holdings in shares of Pfizer by 21.9% during the fourth quarter. Ethos Financial Group LLC now owns 11,390 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 2,044 shares during the last quarter. Inceptionr LLC bought a new position in Pfizer during the fourth quarter worth $229,000. Raymond James Financial Inc. bought a new stake in Pfizer in the 4th quarter valued at $274,694,000. Promus Capital LLC acquired a new stake in Pfizer in the 4th quarter worth $66,000. Finally, Vision Financial Markets LLC bought a new position in shares of Pfizer during the 4th quarter worth about $283,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.66%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.